These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 25368234)

  • 41. Gefitinib enhances the antitumor activity of CPT-11 in vitro and in vivo by inhibiting ABCG2 but not ABCB1: a new clue to circumvent gastrointestinal toxicity risk.
    Inoue Y; Ikegami Y; Sano K; Suzuki T; Yoshida H; Nakamura Y; Nakagawa H; Ishikawa T
    Chemotherapy; 2013; 59(4):260-72. PubMed ID: 24457609
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants.
    Miwa M; Tsukahara S; Ishikawa E; Asada S; Imai Y; Sugimoto Y
    Int J Cancer; 2003 Dec; 107(5):757-63. PubMed ID: 14566825
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.
    Imai Y; Yoshimori M; Fukuda K; Yamagishi H; Ueda Y
    Oncol Rep; 2012 Jun; 27(6):1703-9. PubMed ID: 22426819
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Novel 5' untranslated region variants of BCRP mRNA are differentially expressed in drug-selected cancer cells and in normal human tissues: implications for drug resistance, tissue-specific expression, and alternative promoter usage.
    Nakanishi T; Bailey-Dell KJ; Hassel BA; Shiozawa K; Sullivan DM; Turner J; Ross DD
    Cancer Res; 2006 May; 66(10):5007-11. PubMed ID: 16707421
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dimethoxyaurones: Potent inhibitors of ABCG2 (breast cancer resistance protein).
    Sim HM; Lee CY; Ee PL; Go ML
    Eur J Pharm Sci; 2008 Nov; 35(4):293-306. PubMed ID: 18725288
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
    Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
    Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
    [TBL] [Abstract][Full Text] [Related]  

  • 47. (-)-Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line.
    Farabegoli F; Papi A; Bartolini G; Ostan R; Orlandi M
    Phytomedicine; 2010 Apr; 17(5):356-62. PubMed ID: 20149610
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Acyl-CoA synthetase-4 is implicated in drug resistance in breast cancer cell lines involving the regulation of energy-dependent transporter expression.
    Orlando UD; Castillo AF; Medrano MAR; Solano AR; Maloberti PM; Podesta EJ
    Biochem Pharmacol; 2019 Jan; 159():52-63. PubMed ID: 30414939
    [TBL] [Abstract][Full Text] [Related]  

  • 49. ABCG2 gene amplification and expression in esophageal cancer cells with acquired adriamycin resistance.
    Liu L; Zuo LF; Guo JW
    Mol Med Rep; 2014 Apr; 9(4):1299-304. PubMed ID: 24535197
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural flavonoid.
    Yoshikawa M; Ikegami Y; Sano K; Yoshida H; Mitomo H; Sawada S; Ishikawa T
    J Exp Ther Oncol; 2004 Apr; 4(1):25-35. PubMed ID: 15255290
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Involvement of up-regulation of hepatic breast cancer resistance protein in decreased plasma concentration of 7-ethyl-10-hydroxycamptothecin (SN-38) by coadministration of S-1 in rats.
    Yokoo K; Hamada A; Watanabe H; Matsuzaki T; Imai T; Fujimoto H; Masa K; Imai T; Saito H
    Drug Metab Dispos; 2007 Sep; 35(9):1511-7. PubMed ID: 17537871
    [TBL] [Abstract][Full Text] [Related]  

  • 52. ABCG2 inhibitor YHO-13351 sensitizes cancer stem/initiating-like side population cells to irinotecan.
    Shishido Y; Ueno S; Yamazaki R; Nagaoka M; Matsuzaki T
    Anticancer Res; 2013 Apr; 33(4):1379-86. PubMed ID: 23564776
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effective knock down of very high ABCG2 expression by a hammerhead ribozyme.
    Kowalski P; Farley KM; Lage H; Schneider E
    Anticancer Res; 2004; 24(4):2231-5. PubMed ID: 15330166
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor alpha negative fulvestrant-resistant MCF-7 cells.
    Liu H; Cheng D; Weichel AK; Osipo C; Wing LK; Chen B; Louis TE; Jordan VC
    Int J Oncol; 2006 Nov; 29(5):1237-46. PubMed ID: 17016657
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2.
    Kowalski P; Stein U; Scheffer GL; Lage H
    Cancer Gene Ther; 2002 Jul; 9(7):579-86. PubMed ID: 12082458
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Paeonol reverses paclitaxel resistance in human breast cancer cells by regulating the expression of transgelin 2.
    Cai J; Chen S; Zhang W; Hu S; Lu J; Xing J; Dong Y
    Phytomedicine; 2014 Jun; 21(7):984-91. PubMed ID: 24680370
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Enhanced therapeutic effect of Adriamycin on multidrug resistant breast cancer by the ABCG2-siRNA loaded polymeric nanoparticles assisted with ultrasound.
    Bai M; Shen M; Teng Y; Sun Y; Li F; Zhang X; Xu Y; Duan Y; Du L
    Oncotarget; 2015 Dec; 6(41):43779-90. PubMed ID: 26575421
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Survivin up-regulates the expression of breast cancer resistance protein (BCRP) through attenuating the suppression of p53 on NF-κB expression in MCF-7/5-FU cells.
    Wang QP; Wang Y; Wang XD; Mo XM; Gu J; Lu ZY; Pan ZL; Zhu YX
    Int J Biochem Cell Biol; 2013 Sep; 45(9):2036-44. PubMed ID: 23838170
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Modulation of ABCC1 and ABCG2 proteins by ouabain in human breast cancer cells.
    DA Silva VA; DA Silva KA; Delou JM; DA Fonseca LM; Lopes AG; Capella MA
    Anticancer Res; 2014 Mar; 34(3):1441-8. PubMed ID: 24596392
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Harmful effect of ERβ on BCRP-mediated drug resistance and cell proliferation in ERα/PR-negative breast cancer.
    Li W; Jia M; Qin X; Hu J; Zhang X; Zhou G
    FEBS J; 2013 Dec; 280(23):6128-40. PubMed ID: 24103091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.